Marco Maruzzo

3.4k total citations · 1 hit paper
128 papers, 1.6k citations indexed

About

Marco Maruzzo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Marco Maruzzo has authored 128 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 92 papers in Pulmonary and Respiratory Medicine, 74 papers in Oncology and 30 papers in Surgery. Recurrent topics in Marco Maruzzo's work include Renal cell carcinoma treatment (55 papers), Cancer Immunotherapy and Biomarkers (37 papers) and Bladder and Urothelial Cancer Treatments (22 papers). Marco Maruzzo is often cited by papers focused on Renal cell carcinoma treatment (55 papers), Cancer Immunotherapy and Biomarkers (37 papers) and Bladder and Urothelial Cancer Treatments (22 papers). Marco Maruzzo collaborates with scholars based in Italy, United Kingdom and United States. Marco Maruzzo's co-authors include Umberto Basso, Antonella Brunello, Franco Lumachi, S.M.M. Basso, Ugo De Giorgi, Vittorina Zagonel, Ian Judson, Charlotte Benson, Matteo Santoni and Khin Thway and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Marco Maruzzo

111 papers receiving 1.6k citations

Hit Papers

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell ... 2023 2026 2024 2025 2023 25 50 75
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
    2023 89 citations Laurence Albigès, Mauricio Burotto et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marco Maruzzo Italy 19 837 828 439 292 284 128 1.6k
Yasuhide Miyoshi Japan 24 1.0k 1.2× 593 0.7× 402 0.9× 437 1.5× 281 1.0× 137 2.0k
Kazuyuki Numakura Japan 22 660 0.8× 447 0.5× 450 1.0× 389 1.3× 304 1.1× 152 1.7k
Jesco Pfitzenmaier Germany 21 753 0.9× 390 0.5× 541 1.2× 265 0.9× 277 1.0× 58 1.6k
Gavin Marx Australia 24 735 0.9× 662 0.8× 466 1.1× 211 0.7× 471 1.7× 100 1.8k
L. Austin Doyle United States 27 850 1.0× 881 1.1× 1.1k 2.4× 293 1.0× 398 1.4× 71 2.2k
Yang Yao China 29 1.1k 1.3× 1.2k 1.4× 694 1.6× 333 1.1× 302 1.1× 125 2.4k
Jindřich Fínek Czechia 23 607 0.7× 874 1.1× 368 0.8× 176 0.6× 402 1.4× 161 1.5k
Siu‐Long Yao United States 18 1.0k 1.2× 700 0.8× 459 1.0× 269 0.9× 483 1.7× 43 2.0k
Satoshi Tamada Japan 22 982 1.2× 658 0.8× 587 1.3× 278 1.0× 377 1.3× 69 1.7k
Mireia Margelí Vila Spain 20 416 0.5× 784 0.9× 440 1.0× 174 0.6× 485 1.7× 94 1.4k

Countries citing papers authored by Marco Maruzzo

Since Specialization
Citations

This map shows the geographic impact of Marco Maruzzo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco Maruzzo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco Maruzzo more than expected).

Fields of papers citing papers by Marco Maruzzo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marco Maruzzo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco Maruzzo. The network helps show where Marco Maruzzo may publish in the future.

Co-authorship network of co-authors of Marco Maruzzo

This figure shows the co-authorship network connecting the top 25 collaborators of Marco Maruzzo. A scholar is included among the top collaborators of Marco Maruzzo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marco Maruzzo. Marco Maruzzo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Maruzzo, Marco, Osvaldo Padron, María J. Ribal, et al.. (2025). A PHASE 1 DOSE-ESCALATION STUDY OF UGN-301 (ZALIFRELIMAB) IN PATIENTS WITH RECURRENT NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC). Urologic Oncology Seminars and Original Investigations. 43(3). 54–54.
2.
Stellato, Marco, Pierangela Sepe, Enrico Bronte, et al.. (2025). Real-life Use of Cabozantinib in Front-line therapy for Metastatic Renal Cell Carcinoma: The CabFRONT Study (Meet-URO 24). European Urology Open Science. 82. 1–7.
3.
Bimbatti, Davide, et al.. (2024). Systemic Inflammation Indexes and Risk of Immune-related Adverse Events in Patients With Metastatic Urothelial Carcinoma Treated With Immunotherapy. Anticancer Research. 44(10). 4379–4386. 1 indexed citations
4.
Sweis, Randy F., Pablo Gajate, Rafael Morales‐Barrera, et al.. (2024). Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer. JAMA Oncology. 10(11). 1565–1565. 6 indexed citations
5.
Fratino, Lucia, Jerry Polesel, Emilio Francesco Giunta, et al.. (2024). Instrumental activities of daily living in older patients with metastatic prostate cancer: results from the meet-URO network ADHERE prospective study. Scientific Reports. 14(1). 4949–4949.
6.
Maruzzo, Marco, Elena Verzoni, Giuseppe Procopio, et al.. (2024). Italian Registry on Rare Urological Tumors (Meet-URO-23): The First Analysis on Collecting Duct Carcinoma of the Kidney. Clinical Genitourinary Cancer. 22(5). 102186–102186. 1 indexed citations
7.
Guida, Annalisa, Alessio Gili, Claudia Mosillo, et al.. (2024). Efficacy and Safety of Pembrolizumab plus Axitinib combination for Metastatic Renal Cell Carcinoma in a Real-World Scenario: Data From the Prospective ProPAXI Study. Clinical Genitourinary Cancer. 22(6). 102225–102225.
8.
9.
10.
11.
Catalano, Martina, Ugo De Giorgi, Marco Maruzzo, et al.. (2022). Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma. Biomedicines. 10(10). 2444–2444. 3 indexed citations
12.
Cicchetti, A., Marianna Noale, Paola Dordoni, et al.. (2022). Patient-Factors Influencing the 2-Year Trajectory of Mental and Physical Health in Prostate Cancer Patients. Current Oncology. 29(11). 8244–8260. 1 indexed citations
13.
Roviello, Giandomenico, Martina Catalano, Ugo De Giorgi, et al.. (2022). Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors. Frontiers in Oncology. 12. 918413–918413. 6 indexed citations
14.
Bimbatti, Davide, et al.. (2022). Immune checkpoint inhibitors rechallenge in urological tumors: An extensive review of the literature. Critical Reviews in Oncology/Hematology. 170. 103579–103579. 14 indexed citations
15.
Buja, Alessandra, Claudia Cozzolino, Massimo Rugge, et al.. (2022). Renal cell carcinoma: the population, real world, and cost-of-illness. BMC Urology. 22(1). 206–206. 2 indexed citations
16.
Bersanelli, Melissa, Giulia Mazzaschi, Patrizia Giannatempo, et al.. (2021). Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group). Immunotherapy. 14(2). 107–114. 2 indexed citations
17.
18.
Mollica, Veronica, Matteo Santoni, Marc Matrana, et al.. (2021). Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma. Targeted Oncology. 17(1). 61–68. 68 indexed citations
19.
Banna, Giuseppe Luigi, Rosario Di Quattro, Lorenzo Malatino, et al.. (2020). Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy. Clinical & Translational Oncology. 22(11). 2130–2135. 29 indexed citations
20.
Roma, Anna, Marco Maruzzo, Umberto Basso, et al.. (2014). First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel–Lindau (VHL) disease: clinical outcome and patterns of radiological response. Familial Cancer. 14(2). 309–316. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yasuhide Miyoshi Breakdown of academic impact, for papers by Kazuyuki Numakura Breakdown of academic impact, for papers by Jesco Pfitzenmaier Breakdown of academic impact, for papers by Gavin Marx Breakdown of academic impact, for papers by L. Austin Doyle Breakdown of academic impact, for papers by Yang Yao Breakdown of academic impact, for papers by Jindřich Fínek Breakdown of academic impact, for papers by Siu‐Long Yao Breakdown of academic impact, for papers by Satoshi Tamada Breakdown of academic impact, for papers by Mireia Margelí Vila
Rankless by CCL
2026